A Hepatitis B Breakthrough, Merck’s $1B Bet

Good morning, ! This week we’re diving into the first FDA approved cure for Hepatitis B, biomedical engineering global expansion, and Merck’s $1B RNA bet.

Want to advertise in Healthcare 150? Check out our ad platform, here.

Know someone in the healthcare space who should see this? Forward it their way. Here’s the link.

— The Healthcare150 Team

MICROSURVEY

HEADLINE OF THE WEEK

FDA Approves First Functional-Cure Path for Hepatitis B:

Lifelong Treatment Is No Longer the Only Model

So What? GSK’s Hibsago (bepirovirsen) is the first FDA-approved antisense therapy for chronic hepatitis B and gives eligible patients a pathway to maintain viral control after stopping treatment—potentially shifting a 250M+ patient global market from indefinite viral suppression toward finite, cure-oriented therapy, while validating antisense technology in a major infectious disease. (More)

Finally, a Monday that doesn’t feel like one.

Imagine a Saturday where you're not catching up on the CRM you didn't touch all week. 

HubSpot's new self-updating CRM doesn't wait for you to log back in. Friday's calls are already logged. The deal that needs a nudge Monday morning is already flagged. The automation you set up once keeps running without you thinking about it. None of it needed you over the weekend. 

Customers are already seeing it pay off: 45% more deals closed. Finally, you start Monday caught up, not behind.

Get a Demo

DEAL OF THE WEEK

Merck KGaA’s $1.3B Bet on RNAi

Merck KGaA, Darmstadt, Germany is acquiring Silence Therapeutics for approximately $1.3B in equity value, or $1.1B enterprise value, paying $20.00 per ADS in cash. The price represents a 130% premium, signaling how aggressively strategics are willing to pay for differentiated RNA interference platforms with rare disease potential.

The strategic value sits beyond Silence’s individual programs. Merck gains an siRNA platform that can expand its rare disease pipeline and potentially support multiple future assets, giving the buyer both pipeline depth and platform optionality.

The premium also matters. Paying more than double the unaffected share price suggests scarce, validated RNAi capabilities are being valued less like single asset biotech and more like reusable development infrastructure.

Why it matters: As large pharma searches for growth beyond existing franchises, platform acquisitions are becoming a faster route to pipeline renewal than building capabilities internally. The deal is expected to close in Q1 2027 through a UK scheme of arrangement. (More)

TREND TO WATCH

Biomedical Engineering’s Center of Gravity Is Shifting

Biomedical engineering is scaling faster than the broader research base. Nature Index output in the field increased 70% between 2021 and 2025, while its share of indexed research rose from 2.4% to 2.7%. But growth is increasingly concentrated.

China now accounts for 50.9% of global biomedical engineering output, up from 28.9% in 2021. Outside the two largest markets, the more interesting signal is specialization. South Korea has maintained a leading position, with biomedical engineering representing 4.8% of its total Nature Index output. Its research share also accelerated sharply after 2023.

Meanwhile, Switzerland, Canada, and the Netherlands are building differentiated positions through international collaboration, private sector participation, and broader research networks.

Why it matters: Research concentration today can become commercialization concentration tomorrow. For MedTech companies, investors, and strategic acquirers, South Korea and China increasingly warrant attention as sources of intellectual property, technical talent, and future acquisition targets. The opportunity is shifting from simply tracking research volume to identifying where specialization and commercialization capacity overlap. (More)

DEALS TRACKER

Roche → Hansoh Pharma ADC portfolio (license) | $400M upfront + $110M anniversary payment + >$15B milestones
This is Roche's second ADC deal with Hansoh, and one of the largest China out-licensing deals by milestone value to date. Signed Oct 17, announced Oct 19. Read more


Kohlberg → Alcanza Clinical Research, from Martis Capital | ~$800–850M (reported)
This is a sponsor-to-sponsor sale of a clinical-research site platform. It sets a useful price comparison for the other PE-backed site networks waiting to sell. It's an Axios Pro scoop and not yet confirmed by the companies. Read more

Alcon → Neurotech Pharmaceuticals | $550M + contingent commercial milestones
Alcon picks up ENCELTO, the only FDA-approved treatment for MacTel Type 2, a rare retinal disease, which expands its retina portfolio. The deal closed Oct 20. Read more

Astellas → AI Proteins (research collaboration & license) | >$400M upfront + milestones, plus royalties
Astellas gets an exclusive worldwide license to AI-designed de novo miniprotein drug candidates against undisclosed targets. Announced Oct 21. Read more

INTERESTING ARTICLES